These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37666449)

  • 1. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
    Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
    J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance evaluation of Bruker UMIC
    Bianco G; Boattini M; Comini S; Gaibani P; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):559-566. PubMed ID: 38240988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
    Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
    Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
    Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y
    J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
    Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections.
    El Ghali A; Kunz Coyne AJ; Lucas K; Tieman M; Xhemali X; Lau S-p; Iturralde G; Purdy A; Holger DJ; Garcia E; Veve MP; Rybak MJ
    Microbiol Spectr; 2024 Feb; 12(2):e0310823. PubMed ID: 38206034
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
    Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
    J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.